For example, the TGF-β receptor I kinase inhibitor galunisertib, when combined with anti-PD-L1 therapy, resulted in significant tumor regression and enhanced T cell accumulation in murine HCC models [168]. This evidence concerns the gene CD274 and neoplasm.